Table 2.
Antipsychotic class | Retrospective period |
Baseline n (%) | Prospective period |
|||||
---|---|---|---|---|---|---|---|---|
−12 months n (%) | −9 months n (%) | −6 months n (%) | −3 months n (%) | 3 months n (%) | 6 months n (%) | |||
OA: | Any | 24 (30.4) | 25 (31.6) | 29 (36.7) | 28 (35.4) | 36 (45.6) | 8 (10.1) | 7 (8.9) |
Risperidone | 12 (15.2) | 13 (16.5) | 12 (15.2) | 14 (17.7) | 29 (36.7) | 4 (5.1) | 4 (5.1) | |
Olanzapine | 6 (7.6) | 6 (7.6) | 7 (8.9) | 6 (7.6) | 2 (2.5) | 0 (0) | 0 (0) | |
OC | 15 (19) | 17 (21.5) | 19 (24.1) | 18 (22.8) | 14 (17.7) | 4 (5.1) | 3 (3.8) | |
DC | 9 (11.4) | 10 (12.7) | 9 (11.4) | 10 (12.7) | 2 (2.5) | 0 (0) | 0 (0) | |
RLAI | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 79 (100) | 79 (100) | 78 (98.7) |
Note: Each patient can appear more than once per time point.
Abbreviations: OA, oral atypical; OC, oral conventional; DC, depot conventional; RLAI, risperidone long-acting injectable.